amp945
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2022 (NCT05355298)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Focal adhesion kinase 1ANTAGONIST
PTK2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1- Mol. weight
- 527.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3689071 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07026279 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2025 | Amplia Therapeutics Limited |
| NCT05355298 | Phase 1/Phase 2 (Phase 2) | May 31, 2022 | Amplia Therapeutics Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amplia Therapeutics Limited | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1